Impact of three anti-TNFα biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients

Journal of Clinical Immunology

Volumn 28, Issue 5, 2008, Pages 445-455

  Bacquet Deschryver, H ^a   Jouen, F ^b   Quillard, M ^a   Menard J F ^a   Goeb V ^a   Lequerre T ^a   Mejjad, O ^a   Daragon, A ^a   Tron, F ^b   Le Loet X ^a   Vittecoq, O ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Anti CCP (anti cyclic citrullinated peptide antibodies); Antinuclear antibodies; Rheumatoid arthritis; Spondylarthropathy; Tumor necrosis factors alpha blockers

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS; SPONDYLOARTHROPATHY; TREATMENT DURATION; TREATMENT RESPONSE; ANTIBODY PRODUCTION; BLOOD; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51349146899     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-008-9214-3     Document Type: Article

References (41)

1. T Pincus 1995 Longterm outcomes in RA Br J Rheumatol 34 Suppl 2 59 73
2. RN Maini EW St Clair F Breedveld D Furst J Kalden M Weisman 1999 Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Lancet 354 1932 1939
3. LW Moreland G Margolies LW Heck Jr A Saway C Blosch R Hanna 1996 Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis J Rheumatol 23 1849 1855
4. LW Moreland SW Baumgartner MH Schiff EA Tindall RM Fleischmann AL Weaver 1997 Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 141 147
5. D Van Der Heijde L Klareskog V Rodriguez-Valverde C Codreanu H Bolosiu J Melo-Gomes 2006 Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial Arthritis Rheum 54 1063 1074
6. ME Weinblatt EC Keystone DE Furst LW Moreland MH Weisman CA Birbara 2003 Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 48 35 45
7. D Van Der Heijde B Dijkmans P Geusens J Sieper K De Woody P Williamson 2005 Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 52 582 591
8. JC Davis Jr D van der Heijde J Braun M Dougados J Cush DO Clegg 2003 Enbrel Ankylosing Spondylitis Study Group: recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis Rheum 48 3230 3236
9. D Van Der Heidje A Kivitz MH Schiff J Sieper BA Dijkmans J Braun 2006 Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 54 2136 2146
10. CE Antoni A Kavanaugh B Kirkham Z Tutuncu GR Burmester U Schneider 2005 Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Arthritis Rheum 52 1227 1236
11. PJ Mease AJ Kivitz FX Burch EL Siegel SB Cohen P Ory 2004 Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression Arthritis Rheum 50 2264 2272
12. PJ Mease DD Gladman CT Ritchlin EM Ruderman SD Steinfeld EH Choy 2005 Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 3279 3289
13. T Matsui K Shimada N Ozawa H Hayakawa F Hagiwara H Nakayama 2006 Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis J Rheumatol 33 2390 2397
14. M De Bandt O Vittecoq V Deschamps X Le Loët O Meyer 2003 Anti-TNF-alpha induced systemic lupus syndrome Clin Rheumatol 22 56 61
15. F Bobbio-Pallavicini C Alpini R Caporali S Avalle S Bugatti C Montecucco 2004 Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment Arthritis Res Ther 6 264 272
16. PJ Charles RJ Smeenk J de Jong M Feldmann RN Maini 2000 Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a. Findings in open-label and randomised placebo-controlled trials Arthritis Rheum 43 2383 2390
17. C Alessandri M Bombardieri N Papa M Cinquini L Magrini A Tincani 2004 Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement Ann Rheum Dis 63 1218 1221
18. L De Rycke X Verhelst E Kruithof F Van den Bosch IEA Hoffman EM Veys 2005 Rheumatoid factor but not anti-citrullinated protein antibodies is modulated by infliximab treatment arthritis Ann Rheum Dis 64 299 302
19. E Comby P Tanaff D Mariotte V Costentin-Pignol C Marcelli JJ Ballet 2006 Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with long-term infliximab therapy J Rheumatol 33 24 30
20. P Caramaschi D Biasi E Tonolli S Pieropan N Martinelli A Carletto 2005 Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment Rheumatol Int 26 58 62
21. B Yazdani-Biuki E Stadlmaier A Mulabecirovic R Brezinschek G Tilz U Demel 2005 Blockade of tumour necrosis factor a significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis Ann Rheum Dis 64 1224 1226
22. HA Chen KC Lin CH Chen HT Liao HP Wang HN Chang 2006 The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis Ann Rheum Dis 65 35 39
23. F Atzeni P Sarzi-Puttini D Dell Acqua S de Portu G Cecchini C Cruini 2006 Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study Arthritis Res Ther 8 R3
24. Y Braun-Moscovici D Markovits O Zinder D Schapira A Rozin M Ehrenburg 2006 Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-a therapy in patients with rheumatoid arthritis J Rheumatol 33 497 500
25. C Ferraro-Peyret F Coury JG Tebib J Bienvenu N Fabien 2004 Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study Arthritis Res Ther 6 535 543
26. L De Rycke E Kruithof N Van Damme IE Hoffman N Van den Bossche F Van den Bosch 2003 Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy Arthritis Rheum 48 1015 1023
27. S Keeling A Oswald AS Russell WP Maksymowych 2006 Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup J Rheumatol 33 558 561
28. L De Rycke D Baeten E Kruithof F Van den Bosch EM Veys F De Keyser 2005 Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity Arthritis Rheum 52 2192 2201
29. P Caramaschi D Biasi M Colombatti S Pieropan N Martinelli A Carletto 2006 Anti-TNF alpha therapy in rheumatoid arthritis and autoimmunity Rheumatol Int 26 209 214
30. L De Rycke D Baeten E Kruithof F Van den Bosch EM Veys F De Keyser 2005 The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications Lupus 14 931 937
31. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324
32. JM Moll V Wright 1973 New York clinical criteria for ankylosing spondylitis. A statistical evaluation Ann Rheum Dis 32 354 363
33. V Wright JM Moll 1971 Psoriatic arthritis Bull Rheum Dis 21 627 632
34. J Sellam Y Allanore F Batteux C Job Deslandre B Weill A Kahan 2005 Autoantibody induction in patients with refractory spondylarthropathy treated with infliximab and methotrexate Joint Bone Spine 72 48 52
35. C Eriksson S Engstrand K-G Sundqvist Rantapää-Dahlqvist 2005 Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFa Ann Rheum Dis 64 403 407
36. AI Catrina C Trollmo E af Klint M Engstrom J Lampa Y Hermansson 2005 Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints Arthritis Rheum 52 61 72
37. J Zou M Rudwaleit J Brandt A Thiel J Braun J Sieper 2003 Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept Ann Rheum Dis 62 561 564
38. B Haraoui L Cameron M Ouellet B White 2006 Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response J Rheumatol 33 31 36
39. CJ Van Der Laken AE Voskuyl JC Roos M Stigter van Walsum ER de Groot G Wolbink 2007 Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis Ann Rheum Dis 66 253 256
40. F Bobbio-Pallavicini R Caporali C Alpini S Avalla O Epis C Klersy 2007 High IgA rheumatoid factor levels are associated with poor clinical response to TNF-alpha inhibitors in rheumatoid arthritis Ann Rheum Dis 66 302 370
41. L Klareskog L Padyukov J Ronnelid L Alfredsson 2006 Genes, environment and immunity in the development of rheumatoid arthritis Curr Opin Immunol 18 650 655